89 related articles for article (PubMed ID: 31054856)
1. GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT/GSK3β/CyclinD1 pathway.
Xi J; Sun Y; Zhang M; Fa Z; Wan Y; Min Z; Xu H; Xu C; Tang J
Exp Cell Res; 2019 Aug; 381(1):1-9. PubMed ID: 31054856
[TBL] [Abstract][Full Text] [Related]
2. GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors.
Li Y; Li B; Xu Y; Qian L; Xu T; Meng G; Li H; Wang Y; Zhang L; Jiang X; Liu Q; Xie Y; Cheng C; Sun B; Yu D
Cancer Res; 2022 Sep; 82(18):3223-3235. PubMed ID: 35895805
[TBL] [Abstract][Full Text] [Related]
3. Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study.
Zhang L; Su K; Liu Q; Li B; Wang Y; Cheng C; Li Y; Xu C; Chen J; Wu H; Zhu M; Mai X; Cao Y; Peng J; Yue Y; Ding Y; Yu D
BMC Cancer; 2023 Nov; 23(1):1081. PubMed ID: 37946141
[TBL] [Abstract][Full Text] [Related]
4. CRKL promotes hepatocarcinoma through enhancing glucose metabolism of cancer cells via activating PI3K/Akt.
Guo C; Gao C; Lv X; Zhao D; Greenaway FT; Hao L; Tian Y; Liu S; Sun MZ
J Cell Mol Med; 2021 Mar; 25(5):2714-2724. PubMed ID: 33523562
[TBL] [Abstract][Full Text] [Related]
5. Glutaminase-1 stimulates the proliferation, migration, and survival of human endothelial cells.
Peyton KJ; Liu XM; Yu Y; Yates B; Behnammanesh G; Durante W
Biochem Pharmacol; 2018 Oct; 156():204-214. PubMed ID: 30144404
[TBL] [Abstract][Full Text] [Related]
6. Analysis of anti-tumor effect and mechanism of GLS1 inhibitor CB-839 in colorectal cancer using a stroma-abundant tumor model.
Miyamoto R; Takigawa H; Yuge R; Shimizu D; Ariyoshi M; Otani R; Tsuboi A; Tanaka H; Yamashita K; Hiyama Y; Urabe Y; Ishikawa A; Sentani K; Oka S
Exp Mol Pathol; 2024 Jun; 137():104896. PubMed ID: 38703552
[TBL] [Abstract][Full Text] [Related]
7. AHSA1 Regulates Hepatocellular Carcinoma Progression via the TGF-β/Akt-Cyclin D1/CDK6 Pathway.
Gao Y; Li Y; Liu Z; Dong Y; Yang S; Wu B; Xiao M; Chen C; Wen Y; Chen L; Jiang H; Yao Y
J Hepatocell Carcinoma; 2023; 10():2021-2036. PubMed ID: 38022728
[TBL] [Abstract][Full Text] [Related]
8. IGF2BP3 promotes glutamine metabolism of endometriosis by interacting with UCA1 to enhances the mRNA stability of GLS1.
Wang H; Cao Y; Gou Y; Wang H; Liang Z; Wu Q; Tan J; Liu J; Li Z; Cui J; Zhang H; Zhang Z
Mol Med; 2024 May; 30(1):64. PubMed ID: 38760723
[TBL] [Abstract][Full Text] [Related]
9. Cucurbitacin E inhibits the proliferation of glioblastoma cells via FAK/AKT/GSK3β pathway.
Chen W; Liu F; Lin X; Li L; Chen W; Zhang T; Liu Y; Niu L; Zhang Y; Hu P
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37921057
[TBL] [Abstract][Full Text] [Related]
10. Canagliflozin reduces chemoresistance in hepatocellular carcinoma through PKM2-c-Myc complex-mediated glutamine starvation.
Zeng Y; Jiang H; Zhang X; Xu J; Wu X; Xu Q; Cai W; Ying H; Zhou R; Ding Y; Ying K; Song X; Chen Z; Zeng L; Zhao L; Yu F
Free Radic Biol Med; 2023 Nov; 208():571-586. PubMed ID: 37696420
[TBL] [Abstract][Full Text] [Related]
11. GLS2 Is a Tumor Suppressor and a Regulator of Ferroptosis in Hepatocellular Carcinoma.
Suzuki S; Venkatesh D; Kanda H; Nakayama A; Hosokawa H; Lee E; Miki T; Stockwell BR; Yokote K; Tanaka T; Prives C
Cancer Res; 2022 Sep; 82(18):3209-3222. PubMed ID: 35895807
[TBL] [Abstract][Full Text] [Related]
12. Glutaminase (GLS1) gene expression in primary breast cancer.
Vidula N; Yau C; Rugo HS
Breast Cancer; 2023 Nov; 30(6):1079-1084. PubMed ID: 37679553
[TBL] [Abstract][Full Text] [Related]
13. Identifying strategies to target the metabolic flexibility of tumours.
Méndez-Lucas A; Lin W; Driscoll PC; Legrave N; Novellasdemunt L; Xie C; Charles M; Wilson Z; Jones NP; Rayport S; Rodríguez-Justo M; Li V; MacRae JI; Hay N; Chen X; Yuneva M
Nat Metab; 2020 Apr; 2(4):335-350. PubMed ID: 32694609
[TBL] [Abstract][Full Text] [Related]
14. Targeting glutamine metabolism improves sarcoma response to radiation therapy in vivo.
Patel R; Cooper DE; Kadakia KT; Allen A; Duan L; Luo L; Williams NT; Liu X; Locasale JW; Kirsch DG
Commun Biol; 2024 May; 7(1):608. PubMed ID: 38769385
[TBL] [Abstract][Full Text] [Related]
15. Sortilin-Driven Cancer Secretome Enhances Tumorigenic Properties of Hepatocellular Carcinoma via de Novo Lipogenesis.
Chan KK; Au KY; Suen LH; Leung B; Wong CY; Leow WQ; Lim TK; Ng IO; Chung CY; Lo RC
Am J Pathol; 2023 Dec; 193(12):2156-2171. PubMed ID: 37673328
[TBL] [Abstract][Full Text] [Related]
16. High-fat diet-induced AKT-palmitoylation in hepatocellular carcinoma: a breakthrough mechanistic investigation.
Keating CR; Calvisi DF; Qiu W
Gut; 2024 Jun; 73(7):1046-1048. PubMed ID: 38336464
[No Abstract] [Full Text] [Related]
17. HIF2α-dependent inhibition of mitochondrial clustering of glutaminase suppresses clear cell renal cell carcinoma.
Kim B; Zhao W; Coffey NJ; Bowman CE; Noji M; Jang C; Simon MC; Arany Z
bioRxiv; 2024 May; ():. PubMed ID: 38746132
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of Novel Kidney-Type Glutaminase Allosteric Inhibitors Targeting the Critical Lys-320 Residue.
Song J; Pan C; Li J; Bai R; Zeng Z; Han Y; Chen Z; Hou W; Li Y; Ruan BH
ACS Med Chem Lett; 2023 Jan; 14(1):11-17. PubMed ID: 36655131
[TBL] [Abstract][Full Text] [Related]
19. Enhancing the affinity of novel GLS1 allosteric inhibitors by targeting key residue Lys320.
Zhu L; Chang X; Zhang S; Bai X; Finko AV; Xu X; Bian J; Liu X; Huang H
Future Med Chem; 2023 Aug; 15(15):1393-1414. PubMed ID: 37610850
[No Abstract] [Full Text] [Related]
20. Correction: Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma.
Zhu Q; Zhong AL; Hu H; Zhao JJ; Weng DS; Tang Y; Pan QZ; Zhou ZQ; Song MJ; Yang JY; He JY; Liu Y; Li M; Hu WM; Yang CP; Xiang T; Chen MY; Ma G; Guo L; Xia JC
J Hematol Oncol; 2023 Nov; 16(1):110. PubMed ID: 37925485
[No Abstract] [Full Text] [Related]
[Next] [New Search]
